Syneos Health has announced the acquisition of Illingworth Research Group. Illingworth Research provides in-home and on-site research nursing services for clinical trials in more than 46 countries for the biopharmaceutical and medical device industries. With experience across Phase I–IV studies and a range of therapeutic areas including oncology, respiratory, rare disease and pediatrics, the Company also provides patient-focused CRO services.
“The patient-focused solutions provided by Illingworth Research have never been more relevant as healthcare continues to move closer to the patient. COVID-19 has accelerated this need, benefiting patients who can continue to participate in trials from their homes and sponsors seeking new options built to boost enrollment rates,” said Alistair Macdonald, Chief Executive Officer of Syneos Health.
Illingworth Research Group will maintain its brand, operating as a distinct Syneos Health Business Unit.
For more information, click here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
The State of the Opioid Epidemic
March 26th 2024In part 1 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the current state of opioid usage including how pain treatment is often mismanaged and how the industry can adopt greater safety standards in developing pain therapies.